Telix制药公司报告,2025年的收入增长56%,达到783.2M美元,预计为1.18B-1.23B美元。 Telix Pharmaceuticals reports a 56% revenue jump to $783.2M, forecasts $1.18B-$1.23B for 2025.

Telix制药公司报告说,到2024年为止的财政年度创下了历史新高,收入增加56%,达到7.832亿美元,其驱动因素是其癌症治疗Illuccix的销售。 Telix Pharmaceuticals reported a record financial year ending 2024, with revenue up 56% to $783.2 million, driven by sales of its cancer treatment Illuccix®. 该公司在研发方面投资1.946亿美元,并扩大其全球基础设施。 The company invested $194.6 million in R&D and expanded its global infrastructure. 2025年,Telix预测收入在11.8亿至12.3亿美元之间,并计划推出多种产品和继续发展基础设施。 For 2025, Telix forecasts revenue between $1.18 billion and $1.23 billion, with plans for multiple product launches and continued infrastructure development.